Jomaa Collaborates with Alfred E Tiefenbacher GmbH & Co KG

Jomaa Pharma GmbH are pleased to announce their collaboration with Alfred E Tiefenbacher GmbH & Co KG in a joint venture to accelerate the development of a novel antimalarial treatment.

Hamburg, Germany, 25 April, 2017 – With nearly 200 million malaria cases worldwide and about 450,000 deaths annually, malaria still poses a global health problem especially in Africa. Current first line therapies are all based on artemisinins. These therapies have been in place for over 10 years and are becoming less effective in South East Asia. Should drug resistant strains of the parasite spread to India and especially Africa, the fear is that this development could threaten or even reverse the gains that have been made in the last decade. Historically, this has happened with chloroquine and pyrimethamine in the 1970s and 1980s.

Jomaa Pharma and Alfred E Tiefenbacher are talking to public and private parties to strengthen the efforts to ensure the early availability of this much needed treatment. 

For further information please contact:

Jomaa Pharma:

Dr David Hutchinson
E-mail: david.hutchinson@jomaa-pharma.com
Tel: +44 (0)1959 563487 or
+44 (0)7775 593743

Alfred E Tiefenbacher:

Dr Katharina Wolff
E-mail: k.wolff@aet.eu
Tel: +49 (0) 40 441809 147

 

 

Go back